View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAdderaCare 향후 성장Future 기준 점검 3/6핵심 정보82.8%이익 성장률81.36%EPS 성장률Medical Equipment 이익 성장21.5%매출 성장률4.6%향후 자기자본이익률0.91%애널리스트 커버리지Low마지막 업데이트n/a최근 향후 성장 업데이트Price Target Changed • Nov 16Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 41% above last closing price of kr3.05. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.Major Estimate Revision • Aug 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr266.7m to kr272.1m. Forecast EPS reduced from -kr0.65 to -kr0.84 per share. Medical Equipment industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.80 to kr4.30. Share price rose 4.4% to kr2.37 over the past week.Price Target Changed • Aug 27Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 81% above last closing price of kr2.37. Stock is down 65% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.Major Estimate Revision • Jun 18Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr278.0m to kr266.7m. Now expected to report a loss of kr0.65 per share instead of kr0.04 per share profit previously forecast. Medical Equipment industry in Sweden expected to see average net income growth of 30% next year. Consensus price target down from kr4.95 to kr4.80. Share price fell 14% to kr2.58 over the past week.Major Estimate Revision • May 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr270.1m to kr278.0m. EPS estimate fell from kr0.24 to kr0.04 per share. Net income forecast to shrink 86% next year vs 30% growth forecast for Medical Equipment industry in Sweden . Consensus price target down from kr7.05 to kr4.95. Share price was steady at kr3.03 over the past week.Price Target Changed • May 24Price target decreased to kr4.95Down from kr7.05, the current price target is provided by 1 analyst. New target price is 70% above last closing price of kr2.92. Stock is down 54% over the past year. The company is forecast to post earnings per share of kr0.04 for next year compared to kr0.037 last year.모든 업데이트 보기Recent updates공시 • Jan 11AdderaCare's Directors Applied for the Delisting of Its Shares from Nasdaq StockholmMedCap secured about a 97.16% shareholding in AdderaCare AB after its recommended public offer was extended until January 9, 2023. The Swedish private equity company said on January 6, 2023 it launched the compulsory acquisition of the remaining shares and the settlement for shares tendered during the extension is expected to start around January 16, 2023. AdderaCare's directors applied for the delisting of its shares from Nasdaq Stockholm and the last day of trading is January 20, 2023.공시 • Jan 05AdderaCare AB to Apply for Delisting of Its Shares from Nasdaq First North Growth MarketOn November 17, 2022, the shares in AdderaCare AB (the Company) were given observation status with reference to a public takeover offer from MedCap AB (publ) (“MedCap”) to the shareholders in the Company. On December 23, 2022, MedCap issued a press release with information that MedCap had achieved control of more than 90% of the shares in the Company. The press release also stated that MedCap intended to commence a compulsory acquisition procedure to acquire the remaining shares in the Company, and to seek a delisting of the Company’s shares from Nasdaq First North Growth Market. On January 4, 2023, the Company issued a press release with information that the Company had decided to apply for delisting of its shares from Nasdaq First North Growth Market. Nasdaq Stockholm AB has also received such an application from the Company.공시 • Nov 17MedCap May Promote Delisting of AdderaCar's Shares from Nasdaq First North Growth MarketMedCap AB (publ) announced a recommended public cash offer to the shareholders of AdderaCare AB (AdderaCare AB (publ)) ("Company") to tender all their shares in AdderaCare to MedCap at a price of SEK 3.60 in cash per share (the "Offer"). The shares in AdderaCare are admitted to trading on Nasdaq First North Growth Market, under the ticker ADDERA. In the event that MedCap, whether in connection with the Offer or otherwise, acquires shares representing more than 90% of the total number of shares of AdderaCare, MedCap intends to initiate a compulsory buy-out procedure with respect to the remaining shares. In connection therewith, MedCap may promote delisting of AdderaCare's shares from Nasdaq First North Growth Market.Price Target Changed • Nov 16Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 41% above last closing price of kr3.05. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.Valuation Update With 7 Day Price Move • Sep 01Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr2.60, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 17x in the Medical Equipment industry in Sweden. Total loss to shareholders of 45% over the past three years.분석 기사 • Aug 31Is Now An Opportune Moment To Examine AdderaCare AB (STO:ADDERA)?AdderaCare AB ( STO:ADDERA ), is not the largest company out there, but it saw a double-digit share price rise of over...Major Estimate Revision • Aug 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr266.7m to kr272.1m. Forecast EPS reduced from -kr0.65 to -kr0.84 per share. Medical Equipment industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.80 to kr4.30. Share price rose 4.4% to kr2.37 over the past week.Price Target Changed • Aug 27Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 81% above last closing price of kr2.37. Stock is down 65% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr2.44, the stock trades at a trailing P/E ratio of 16.7x. Average forward P/E is 20x in the Medical Equipment industry in Sweden. Total loss to shareholders of 57% over the past three years.Major Estimate Revision • Jun 18Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr278.0m to kr266.7m. Now expected to report a loss of kr0.65 per share instead of kr0.04 per share profit previously forecast. Medical Equipment industry in Sweden expected to see average net income growth of 30% next year. Consensus price target down from kr4.95 to kr4.80. Share price fell 14% to kr2.58 over the past week.분석 기사 • Jun 18We Think AdderaCare (STO:ADDERA) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Major Estimate Revision • May 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr270.1m to kr278.0m. EPS estimate fell from kr0.24 to kr0.04 per share. Net income forecast to shrink 86% next year vs 30% growth forecast for Medical Equipment industry in Sweden . Consensus price target down from kr7.05 to kr4.95. Share price was steady at kr3.03 over the past week.Price Target Changed • May 24Price target decreased to kr4.95Down from kr7.05, the current price target is provided by 1 analyst. New target price is 70% above last closing price of kr2.92. Stock is down 54% over the past year. The company is forecast to post earnings per share of kr0.04 for next year compared to kr0.037 last year.Reported Earnings • May 21First quarter 2022 earnings: Revenues exceed analyst expectationsFirst quarter 2022 results: Revenue: kr68.4m (up 51% from 1Q 2021). Net income: kr306.0k (up kr3.70m from 1Q 2021). Profit margin: 0.4% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 3.3%, compared to a 126% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Chairman of the Board Hans Andersson is the most experienced director on the board, commencing their role in 2019. Independent Director Bengt Olsson was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.분석 기사 • Apr 06Investors Could Be Concerned With AdderaCare's (STO:ADDERA) Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...Major Estimate Revision • Mar 03Consensus EPS estimates increase by 243%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from kr265.0m to kr270.1m. EPS estimate increased from kr0.07 to kr0.24 per share. Net income forecast to grow 545% next year vs 26% growth forecast for Medical Equipment industry in Sweden. Consensus price target up from kr6.90 to kr7.05. Share price rose 7.4% to kr4.22 over the past week.Reported Earnings • Feb 28Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: kr0.037 (down from kr0.45 in FY 2020). Revenue: kr247.8m (up 21% from FY 2020). Net income: kr1.24m (down 88% from FY 2020). Profit margin: 0.5% (down from 4.9% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is forecast to grow 6.9%, compared to a 84% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.분석 기사 • Jan 27AdderaCare (STO:ADDERA) Has A Pretty Healthy Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Nov 20AdderaCare (STO:ADDERA) Will Want To Turn Around Its Return TrendsIf you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...Reported Earnings • Nov 14Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: kr61.1m (up 20% from 3Q 2020). Net income: kr178.0k (down 90% from 3Q 2020). Profit margin: 0.3% (down from 3.5% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 12Price target decreased to kr6.90Down from kr7.45, the current price target is provided by 1 analyst. New target price is 21% above last closing price of kr5.70. Stock is up 63% over the past year. The company is forecast to post earnings per share of kr0.02 for next year compared to kr0.45 last year.Reported Earnings • Aug 29Second quarter 2021 earnings releasedThe company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr61.6m (up 41% from 2Q 2020). Net income: kr418.0k (down 96% from 2Q 2020). Profit margin: 0.7% (down from 21% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.분석 기사 • Aug 29These 4 Measures Indicate That AdderaCare (STO:ADDERA) Is Using Debt Reasonably WellSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr7.10, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 36x in the Medical Equipment industry in Sweden. Negligible returns to shareholders over past three years.분석 기사 • Aug 02AdderaCare (STO:ADDERA) Could Be Struggling To Allocate CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...분석 기사 • May 24What Does AdderaCare AB's (STO:ADDERA) Share Price Indicate?AdderaCare AB ( STO:ADDERA ), is not the largest company out there, but it saw a significant share price rise of over...Reported Earnings • May 15First quarter 2021 earnings releasedThe company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr45.4m (down 5.3% from 1Q 2020). Net loss: kr3.39m (loss narrowed 10% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.분석 기사 • Apr 28Here's What's Concerning About AdderaCare's (STO:ADDERA) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Valuation Update With 7 Day Price Move • Mar 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr6.25, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 29x in the Medical Equipment industry in Sweden. Total loss to shareholders of 30% over the past three years.분석 기사 • Mar 03We Think That There Are Some Issues For AdderaCare (STO:ADDERA) Beyond Its Promising EarningsAdderaCare AB ( STO:ADDERA ) just released a solid earnings report, and the stock displayed some strength. However, we...Reported Earnings • Feb 28Full year 2020 earnings released: EPS kr0.38 (vs kr0.10 loss in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: kr205.2m (flat on FY 2019). Net income: kr9.96m (up kr11.8m from FY 2019). Profit margin: 4.9% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.9%. Over the next year, revenue is forecast to grow 5.7%, compared to a 452% growth forecast for the Medical Equipment industry in Sweden.Is New 90 Day High Low • Feb 25New 90-day high: kr6.10The company is up 71% from its price of kr3.56 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr6.10, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 23.3x. This compares to an average P/E of 43x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 30%.분석 기사 • Feb 20Is There Now An Opportunity In AdderaCare AB (STO:ADDERA)?AdderaCare AB ( STO:ADDERA ), might not be a large cap stock, but it led the OM gainers with a relatively large price...Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improved over the past weekAfter last week's 22% share price gain to kr5.20, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 36x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 47%.Is New 90 Day High Low • Feb 02New 90-day high: kr5.20The company is up 56% from its price of kr3.34 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 19% over the same period.분석 기사 • Jan 16We Think AdderaCare (STO:ADDERA) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Jan 04New 90-day high: kr4.74The company is up 44% from its price of kr3.30 on 06 October 2020. The Swedish market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period.Is New 90 Day High Low • Dec 16New 90-day high: kr4.28The company is up 25% from its price of kr3.42 on 16 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 20% share price gain to kr4.20, the stock is trading at a trailing P/E ratio of 18.6x, up from the previous P/E ratio of 15.5x. This compares to an average P/E of 33x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 58%.Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 22% share price gain to kr4.20, the stock is trading at a trailing P/E ratio of 18.6x, up from the previous P/E ratio of 15.2x. This compares to an average P/E of 32x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 61%.Is New 90 Day High Low • Nov 30New 90-day high: kr3.60The company is up 3.0% from its price of kr3.50 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Medical Equipment industry, which is also up 3.0% over the same period.분석 기사 • Nov 22Is It Time To Consider Buying AdderaCare AB (STO:ADDERA)?While AdderaCare AB (STO:ADDERA) might not be the most widely known stock at the moment, it saw a significant share...이익 및 매출 성장 예측OM:ADDERA - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20253082N/A23112/31/2024307-1N/A15112/31/2023282-1N/A14112/31/2022259-29N/A1919/30/2022279-27911N/A6/30/2022283-251719N/A3/31/202227151619N/A12/31/202124811416N/A9/30/202123101214N/A6/30/20212212911N/A3/31/2021203101415N/A12/31/2020205101416N/A9/30/202019851414N/A6/30/2020199577N/A3/31/2020208-456N/A12/31/2019206-278N/A9/30/2019206358N/A6/30/201920111012N/A3/31/2019203379N/A12/31/201819212124N/A9/30/2018177179N/A6/30/201816111215N/A3/31/2018136-12226N/A12/31/20171284913N/A9/30/201711651621N/A6/30/20171054-23N/A3/31/20171027-8-6N/A12/31/2016946-10-9N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ADDERA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(0.4%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: ADDERA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: ADDERA 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: ADDERA 의 수익(연간 4.6%)이 Swedish 시장(연간 0.08%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: ADDERA 의 수익(연간 4.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ADDERA의 자본 수익률은 3년 후 0.9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/01/12 10:39종가2023/01/12 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AdderaCare AB는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mats HyttingeCarlsquare AB
Price Target Changed • Nov 16Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 41% above last closing price of kr3.05. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.
Major Estimate Revision • Aug 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr266.7m to kr272.1m. Forecast EPS reduced from -kr0.65 to -kr0.84 per share. Medical Equipment industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.80 to kr4.30. Share price rose 4.4% to kr2.37 over the past week.
Price Target Changed • Aug 27Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 81% above last closing price of kr2.37. Stock is down 65% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.
Major Estimate Revision • Jun 18Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr278.0m to kr266.7m. Now expected to report a loss of kr0.65 per share instead of kr0.04 per share profit previously forecast. Medical Equipment industry in Sweden expected to see average net income growth of 30% next year. Consensus price target down from kr4.95 to kr4.80. Share price fell 14% to kr2.58 over the past week.
Major Estimate Revision • May 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr270.1m to kr278.0m. EPS estimate fell from kr0.24 to kr0.04 per share. Net income forecast to shrink 86% next year vs 30% growth forecast for Medical Equipment industry in Sweden . Consensus price target down from kr7.05 to kr4.95. Share price was steady at kr3.03 over the past week.
Price Target Changed • May 24Price target decreased to kr4.95Down from kr7.05, the current price target is provided by 1 analyst. New target price is 70% above last closing price of kr2.92. Stock is down 54% over the past year. The company is forecast to post earnings per share of kr0.04 for next year compared to kr0.037 last year.
공시 • Jan 11AdderaCare's Directors Applied for the Delisting of Its Shares from Nasdaq StockholmMedCap secured about a 97.16% shareholding in AdderaCare AB after its recommended public offer was extended until January 9, 2023. The Swedish private equity company said on January 6, 2023 it launched the compulsory acquisition of the remaining shares and the settlement for shares tendered during the extension is expected to start around January 16, 2023. AdderaCare's directors applied for the delisting of its shares from Nasdaq Stockholm and the last day of trading is January 20, 2023.
공시 • Jan 05AdderaCare AB to Apply for Delisting of Its Shares from Nasdaq First North Growth MarketOn November 17, 2022, the shares in AdderaCare AB (the Company) were given observation status with reference to a public takeover offer from MedCap AB (publ) (“MedCap”) to the shareholders in the Company. On December 23, 2022, MedCap issued a press release with information that MedCap had achieved control of more than 90% of the shares in the Company. The press release also stated that MedCap intended to commence a compulsory acquisition procedure to acquire the remaining shares in the Company, and to seek a delisting of the Company’s shares from Nasdaq First North Growth Market. On January 4, 2023, the Company issued a press release with information that the Company had decided to apply for delisting of its shares from Nasdaq First North Growth Market. Nasdaq Stockholm AB has also received such an application from the Company.
공시 • Nov 17MedCap May Promote Delisting of AdderaCar's Shares from Nasdaq First North Growth MarketMedCap AB (publ) announced a recommended public cash offer to the shareholders of AdderaCare AB (AdderaCare AB (publ)) ("Company") to tender all their shares in AdderaCare to MedCap at a price of SEK 3.60 in cash per share (the "Offer"). The shares in AdderaCare are admitted to trading on Nasdaq First North Growth Market, under the ticker ADDERA. In the event that MedCap, whether in connection with the Offer or otherwise, acquires shares representing more than 90% of the total number of shares of AdderaCare, MedCap intends to initiate a compulsory buy-out procedure with respect to the remaining shares. In connection therewith, MedCap may promote delisting of AdderaCare's shares from Nasdaq First North Growth Market.
Price Target Changed • Nov 16Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 41% above last closing price of kr3.05. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.
Valuation Update With 7 Day Price Move • Sep 01Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr2.60, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 17x in the Medical Equipment industry in Sweden. Total loss to shareholders of 45% over the past three years.
분석 기사 • Aug 31Is Now An Opportune Moment To Examine AdderaCare AB (STO:ADDERA)?AdderaCare AB ( STO:ADDERA ), is not the largest company out there, but it saw a double-digit share price rise of over...
Major Estimate Revision • Aug 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr266.7m to kr272.1m. Forecast EPS reduced from -kr0.65 to -kr0.84 per share. Medical Equipment industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.80 to kr4.30. Share price rose 4.4% to kr2.37 over the past week.
Price Target Changed • Aug 27Price target decreased to kr4.30Down from kr4.80, the current price target is provided by 1 analyst. New target price is 81% above last closing price of kr2.37. Stock is down 65% over the past year. The company is forecast to post a net loss per share of kr0.84 compared to earnings per share of kr0.037 last year.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr2.44, the stock trades at a trailing P/E ratio of 16.7x. Average forward P/E is 20x in the Medical Equipment industry in Sweden. Total loss to shareholders of 57% over the past three years.
Major Estimate Revision • Jun 18Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr278.0m to kr266.7m. Now expected to report a loss of kr0.65 per share instead of kr0.04 per share profit previously forecast. Medical Equipment industry in Sweden expected to see average net income growth of 30% next year. Consensus price target down from kr4.95 to kr4.80. Share price fell 14% to kr2.58 over the past week.
분석 기사 • Jun 18We Think AdderaCare (STO:ADDERA) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Major Estimate Revision • May 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from kr270.1m to kr278.0m. EPS estimate fell from kr0.24 to kr0.04 per share. Net income forecast to shrink 86% next year vs 30% growth forecast for Medical Equipment industry in Sweden . Consensus price target down from kr7.05 to kr4.95. Share price was steady at kr3.03 over the past week.
Price Target Changed • May 24Price target decreased to kr4.95Down from kr7.05, the current price target is provided by 1 analyst. New target price is 70% above last closing price of kr2.92. Stock is down 54% over the past year. The company is forecast to post earnings per share of kr0.04 for next year compared to kr0.037 last year.
Reported Earnings • May 21First quarter 2022 earnings: Revenues exceed analyst expectationsFirst quarter 2022 results: Revenue: kr68.4m (up 51% from 1Q 2021). Net income: kr306.0k (up kr3.70m from 1Q 2021). Profit margin: 0.4% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 3.3%, compared to a 126% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Chairman of the Board Hans Andersson is the most experienced director on the board, commencing their role in 2019. Independent Director Bengt Olsson was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
분석 기사 • Apr 06Investors Could Be Concerned With AdderaCare's (STO:ADDERA) Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...
Major Estimate Revision • Mar 03Consensus EPS estimates increase by 243%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from kr265.0m to kr270.1m. EPS estimate increased from kr0.07 to kr0.24 per share. Net income forecast to grow 545% next year vs 26% growth forecast for Medical Equipment industry in Sweden. Consensus price target up from kr6.90 to kr7.05. Share price rose 7.4% to kr4.22 over the past week.
Reported Earnings • Feb 28Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: kr0.037 (down from kr0.45 in FY 2020). Revenue: kr247.8m (up 21% from FY 2020). Net income: kr1.24m (down 88% from FY 2020). Profit margin: 0.5% (down from 4.9% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is forecast to grow 6.9%, compared to a 84% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
분석 기사 • Jan 27AdderaCare (STO:ADDERA) Has A Pretty Healthy Balance SheetHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Nov 20AdderaCare (STO:ADDERA) Will Want To Turn Around Its Return TrendsIf you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...
Reported Earnings • Nov 14Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: kr61.1m (up 20% from 3Q 2020). Net income: kr178.0k (down 90% from 3Q 2020). Profit margin: 0.3% (down from 3.5% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 12Price target decreased to kr6.90Down from kr7.45, the current price target is provided by 1 analyst. New target price is 21% above last closing price of kr5.70. Stock is up 63% over the past year. The company is forecast to post earnings per share of kr0.02 for next year compared to kr0.45 last year.
Reported Earnings • Aug 29Second quarter 2021 earnings releasedThe company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr61.6m (up 41% from 2Q 2020). Net income: kr418.0k (down 96% from 2Q 2020). Profit margin: 0.7% (down from 21% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 29These 4 Measures Indicate That AdderaCare (STO:ADDERA) Is Using Debt Reasonably WellSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr7.10, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 36x in the Medical Equipment industry in Sweden. Negligible returns to shareholders over past three years.
분석 기사 • Aug 02AdderaCare (STO:ADDERA) Could Be Struggling To Allocate CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
분석 기사 • May 24What Does AdderaCare AB's (STO:ADDERA) Share Price Indicate?AdderaCare AB ( STO:ADDERA ), is not the largest company out there, but it saw a significant share price rise of over...
Reported Earnings • May 15First quarter 2021 earnings releasedThe company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr45.4m (down 5.3% from 1Q 2020). Net loss: kr3.39m (loss narrowed 10% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 28Here's What's Concerning About AdderaCare's (STO:ADDERA) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr6.25, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 29x in the Medical Equipment industry in Sweden. Total loss to shareholders of 30% over the past three years.
분석 기사 • Mar 03We Think That There Are Some Issues For AdderaCare (STO:ADDERA) Beyond Its Promising EarningsAdderaCare AB ( STO:ADDERA ) just released a solid earnings report, and the stock displayed some strength. However, we...
Reported Earnings • Feb 28Full year 2020 earnings released: EPS kr0.38 (vs kr0.10 loss in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: kr205.2m (flat on FY 2019). Net income: kr9.96m (up kr11.8m from FY 2019). Profit margin: 4.9% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 3.9%. Over the next year, revenue is forecast to grow 5.7%, compared to a 452% growth forecast for the Medical Equipment industry in Sweden.
Is New 90 Day High Low • Feb 25New 90-day high: kr6.10The company is up 71% from its price of kr3.56 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to kr6.10, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 23.3x. This compares to an average P/E of 43x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 30%.
분석 기사 • Feb 20Is There Now An Opportunity In AdderaCare AB (STO:ADDERA)?AdderaCare AB ( STO:ADDERA ), might not be a large cap stock, but it led the OM gainers with a relatively large price...
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improved over the past weekAfter last week's 22% share price gain to kr5.20, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 36x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 47%.
Is New 90 Day High Low • Feb 02New 90-day high: kr5.20The company is up 56% from its price of kr3.34 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 19% over the same period.
분석 기사 • Jan 16We Think AdderaCare (STO:ADDERA) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Jan 04New 90-day high: kr4.74The company is up 44% from its price of kr3.30 on 06 October 2020. The Swedish market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period.
Is New 90 Day High Low • Dec 16New 90-day high: kr4.28The company is up 25% from its price of kr3.42 on 16 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 20% share price gain to kr4.20, the stock is trading at a trailing P/E ratio of 18.6x, up from the previous P/E ratio of 15.5x. This compares to an average P/E of 33x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 58%.
Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 22% share price gain to kr4.20, the stock is trading at a trailing P/E ratio of 18.6x, up from the previous P/E ratio of 15.2x. This compares to an average P/E of 32x in the Medical Equipment industry in Sweden. Total return to shareholders over the past three years is a loss of 61%.
Is New 90 Day High Low • Nov 30New 90-day high: kr3.60The company is up 3.0% from its price of kr3.50 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Medical Equipment industry, which is also up 3.0% over the same period.
분석 기사 • Nov 22Is It Time To Consider Buying AdderaCare AB (STO:ADDERA)?While AdderaCare AB (STO:ADDERA) might not be the most widely known stock at the moment, it saw a significant share...